tiprankstipranks
Trending News
More News >
VITA 34 AG (DE:V3V)
XETRA:V3V
Advertisement

VITA 34 (V3V) AI Stock Analysis

Compare
0 Followers

Top Page

DE:V3V

VITA 34

(XETRA:V3V)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 4o)
Rating:50Neutral
Price Target:
€7.00
▲(21.74% Upside)
The overall stock score of 50 reflects significant financial challenges, including ongoing losses and high leverage, which are major concerns. However, positive technical indicators provide some optimism, suggesting potential short-term price momentum. The negative P/E ratio and lack of dividend yield weigh on the valuation, limiting the stock's attractiveness.

VITA 34 (V3V) vs. iShares MSCI Germany ETF (EWG)

VITA 34 Business Overview & Revenue Model

Company DescriptionVITA 34 AG engages in the collection, processing, and storage of stem cells from umbilical cord blood and tissue in Germany, Spain, and internationally. It also develops cell therapeutic procedures; cell and gene therapies; cryopreservation of endogenous immune cells; and CAR-T. In addition, the company manufactures advanced therapy medicinal products based on mesenchymal stem cells for experimental treatment by specialized medical institutions; preserves stem cells from perinatal tissue and adult body fat; and engages in the contract manufacturing of pharmaceutical intermediates. VITA 34 AG was founded in 1997 and is based in Leipzig, Germany.
How the Company Makes MoneyVITA 34 generates revenue primarily through its stem cell banking services, which include the collection, processing, and long-term storage of umbilical cord blood and tissue. The company charges fees for initial service packages, which encompass the collection and processing of stem cells at the time of birth, as well as ongoing annual storage fees. Additionally, VITA 34 may earn income from partnerships with healthcare institutions and research organizations, as well as from the sale of stem cell-related products and services. Collaborations with hospitals and clinics to promote their banking services can also contribute to revenue growth, alongside potential revenue from licensing agreements or research funding.

VITA 34 Financial Statement Overview

Summary
VITA 34 is experiencing financial difficulties with ongoing losses, high leverage, and weak cash flow generation. The income statement shows modest revenue growth but negative profitability metrics. The balance sheet indicates significant leverage with a high debt-to-equity ratio, and cash flow analysis reveals liquidity concerns with a significant decline in free cash flow.
Income Statement
45
Neutral
VITA 34's income statement reflects a challenging financial position. The company has experienced modest revenue growth, with a TTM (Trailing-Twelve-Months) revenue growth rate of 2.35%. However, profitability metrics are concerning, with negative net profit and EBIT margins indicating ongoing losses. The gross profit margin has improved slightly to 27.61% in the TTM, but the company remains unprofitable, which is a significant weakness.
Balance Sheet
40
Negative
The balance sheet shows a high debt-to-equity ratio of 1.50, indicating significant leverage and potential financial risk. Return on equity is negative, reflecting the company's inability to generate profits from shareholders' equity. The equity ratio is relatively low, suggesting limited financial stability. These factors highlight the company's financial vulnerability.
Cash Flow
35
Negative
Cash flow analysis reveals a significant decline in free cash flow, with a growth rate of -79.51% in the TTM. The operating cash flow to net income ratio is low, indicating challenges in converting earnings into cash. The free cash flow to net income ratio is also weak, suggesting limited cash generation relative to losses. These metrics highlight cash flow constraints and liquidity concerns.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue87.73M82.18M77.06M68.94M28.42M20.07M
Gross Profit24.23M20.65M28.24M2.73M12.44M11.66M
EBITDA2.80M-443.00K5.81M-18.34M949.00K5.01M
Net Income-9.95M-12.14M-1.86M-27.39M-3.93M1.45M
Balance Sheet
Total Assets157.42M152.74M158.36M151.51M177.95M58.46M
Cash, Cash Equivalents and Short-Term Investments11.50M18.46M17.42M18.23M35.26M10.52M
Total Debt19.67M18.10M21.57M28.18M32.32M5.30M
Total Liabilities145.65M139.83M135.58M135.66M136.00M28.93M
Stockholders Equity13.15M14.13M23.56M16.50M43.07M29.55M
Cash Flow
Free Cash Flow771.00K5.46M5.06M-10.92M467.00K3.33M
Operating Cash Flow4.59M8.65M9.15M-4.49M2.73M3.98M
Investing Cash Flow-7.68M-3.08M-3.57M-5.81M24.87M-252.00K
Financing Cash Flow45.00K-6.09M-5.09M-6.27M-4.70M-2.43M

VITA 34 Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price5.75
Price Trends
50DMA
5.91
Negative
100DMA
5.08
Positive
200DMA
4.59
Positive
Market Momentum
MACD
-0.10
Positive
RSI
40.26
Neutral
STOCH
6.28
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:V3V, the sentiment is Neutral. The current price of 5.75 is below the 20-day moving average (MA) of 6.44, below the 50-day MA of 5.91, and above the 200-day MA of 4.59, indicating a neutral trend. The MACD of -0.10 indicates Positive momentum. The RSI at 40.26 is Neutral, neither overbought nor oversold. The STOCH value of 6.28 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:V3V.

VITA 34 Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
66
Neutral
78.35M-0.6811.53%6.56%180.19%-196.45%
64
Neutral
109.20M23.2216.98%0.21%7.53%
50
Neutral
€98.49M27.28-53.67%11.30%-3316.77%
43
Neutral
23.07M-1.7519.68%11.43%7.72%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
DE:V3V
VITA 34
5.75
1.21
26.65%
DE:MAK
MATERNUS-Kliniken AG
1.10
-0.73
-39.89%
DE:LIK
Limes Schlosskliniken AG
364.00
-6.00
-1.62%
DE:HAEK
HAEMATO AG
10.20
-5.14
-33.51%
DE:JTH0
Gesundheitswelt Chiemgau AG
11.00
-1.18
-9.69%
DE:93M1
MPH Health Care AG
18.30
-3.87
-17.46%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 04, 2025